ArticleJournal of computer-aided molecular design2025
Theoretical investigation of AKT1 mutations in breast cancer: a computational approach to structural and functional insights.
Article in Journal of computer-aided molecular design, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Computational insights into synergistic mechanisms of PD-901 and 5-azacitidine targeting PTPN11 (SHP2) E76K mutation in juvenile myelomonocytic leukemia.Frontiers in bioinformatics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer is a complex disease primarily driven by genetic mutations that disrupt crucial signaling pathways, with the AKT1 gene playing a central role in its progression. This study explores the impact of AKT1 mutations using Whole Exome Sequencing (WES), bioinformatics, and computational modeling. Using WES, we identified and prioritized significant mutations in patient samples, specifically D3N, V337M, and D3N-E169G. Comprehensive sequence and structural analyses were conducted to understand how these mutations affect specific functional domains of the AKT1 protein. To investigate the molecular consequences, molecular docking studies were performed to assess the binding affinity of AKT1 mutations with MK2206, a known allosteric inhibitor of AKT1. The docking results revealed substantial differences in interaction energies, indicating impaired inhibitor binding due to these mutations. Additionally, molecular dynamics simulations over a 500-nanosecond trajectory provided detailed insights into the structural perturbations caused by these mutations. This integrated study, combining genomic and computational approaches, offers a comprehensive understanding of how AKT1 mutations contribute to BC pathogenesis. These findings enhance our knowledge of the molecular mechanisms underlying the disease and support the development of targeted therapies to address the altered behavior of mutated AKT1, advancing personalized treatment strategies for BC.
Indexed as
Identifiers
40343619What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.